Abiopharma

🔍 Kemps-Polanco Reshema (Director)

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 1,438 shares of Common Stock at $177.62 per share (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,028.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 535 shares of Common Stock at $177.62 per share (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 4,563.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The unvested restricted stock units vest upon the earlier of 5/8/2027 or the business day prior to the Company's next annual meeting of shareholders.
• F2: The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.